APA (7th ed.) Citation

S, P., A, C., C, V., FE, P., P, M., C, R., . . . F, G. (2026). Intermediate doses cytarabine after induction with CPX-351 for patients with secondary AML: Safety and efficacy. Annals of hematology, 105(3), 110. https://doi.org/10.1007/s00277-026-06784-w

Chicago Style (17th ed.) Citation

S, Perrone, et al. "Intermediate Doses Cytarabine After Induction with CPX-351 for Patients with Secondary AML: Safety and Efficacy." Annals of Hematology 105, no. 3 (2026): 110. https://doi.org/10.1007/s00277-026-06784-w.

MLA (9th ed.) Citation

S, Perrone, et al. "Intermediate Doses Cytarabine After Induction with CPX-351 for Patients with Secondary AML: Safety and Efficacy." Annals of Hematology, vol. 105, no. 3, 2026, p. 110, https://doi.org/10.1007/s00277-026-06784-w.